Lowers the risk of MI, stroke, revascularization procedures, and angina. ANDA 202357, held by Dr Reddys Labs Ltd. Atorvastatin Calcium.
As of Nov 16, 2026, ANDA 202357 (Atorvastatin Calcium), held by Dr Reddys Labs Ltd, was first approved by FDA on Jul 17, 2012, with 13 approved supplements and 0 published complete response letters.
Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 17, 2012 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Atorvastatin CalciumEQ 80MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Apr 25, 2023 | Supplement 21Labeling · Standard review | Approved | None posted |
| May 4, 2021 | Supplement 17Labeling · Standard review | Approved | None posted |
| May 4, 2021 | Supplement 16Labeling · Standard review | Approved | None posted |
| May 4, 2021 | Supplement 15Labeling · Standard review | Approved | None posted |
| May 4, 2021 | Supplement 14Labeling · Standard review | Approved | None posted |
| Oct 22, 2019 | Supplement 13Labeling · Standard review | Approved | None posted |
| Oct 22, 2019 | Supplement 11Labeling · Standard review | Approved | None posted |
| Oct 22, 2019 | Supplement 9Labeling · Standard review | Approved | None posted |
| Oct 22, 2019 | Supplement 8Labeling · Standard review | Approved | None posted |
| Oct 6, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 4, 2014 | Supplement 4Labeling · Standard review | Approved | None posted |
| Dec 29, 2012 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 27, 2012 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 17, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters